CRDL

Cardiol Therapeutics Inc.

Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. A6· CIK 0001702123 Biotech & Drug Discovery

$1.12 +0.00 (+0.00%)

Oct 26 4:00 PM ET · prev $1.12

Market cap

$138.8M

Micro cap

Consensus

Buy

88% Buy or better · 8 analysts

Median target

🔒 Subscribers only

1 year

−8.2%

from $1.22 · Oct 27

30 days

−33.7%

from $1.69

52-week range

$0.9260–2.29

−51% from high · low Mar 20

Avg volume 20D

1.50M

Oct 6 spike 4.71M

Short interest

🔒 Subscribers only

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read BULLISH 7 reports · 90 days

Balance 0 bearish · 3 bullish · 4 neutral oldest → newest, height = score

Avg score

·High conf. 5/7

Strongest BULLISH Cardiol Therapeutics announced it achieved the original 110-patient enrollment target for its Phase III…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Apr 1 Cardiol Therapeutics announced positive clinical progress across its…
R May 7 Cardiol Therapeutics announced that its Phase II MAvERIC results for…
X Aug 31 Short interest jumps 26.7% to 2.93M
R Sep 23 Cardiol Therapeutics announced it achieved the original 110-patient…

Signal stack

Where each data set points today.

InstitutionsMIXED

Q2 2026: 3 added (0 new), 3 trimmed or exited.
AnalystsBULLISH

7 of 8 rate it Buy or better.
EstimatesRISING

Current-quarter EPS estimate −$0.103 → −$0.076 over 90 days. 1 up, 0 down in 30 days.
TrendDOWNTREND

33% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
RENAISSANCE TECHNOLOGIES LLC	DOUBLED	772,837	$819.2K
MORGAN STANLEY	ADD	355,030	$376.3K
JANE STREET GROUP, LLC	TRIM	53,416	$56.1K
Quadrature Capital Ltd	TRIM	30,566	$32.4K
ROYAL BANK OF CANADA	TRIM	6,729	$7.0K
BARCLAYS PLC	ADD	300	$318.00
MORGAN STANLEY	TRIM	250,421	$338.1K
JANE STREET GROUP, LLC	DOUBLED	126,957	$172.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

8 analysts

Buy 88% rate it Buy or better

Strong Buy2Buy5Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access

Recent actions

Date	Firm	Action	Rating
Sep 23, 2026	HC Wainwright & Co. REITERATE	REITERATE	Buy
Aug 17, 2026	Canaccord Genuity MAINTAIN	MAINTAIN	Buy
Jul 14, 2026	HC Wainwright & Co. REITERATE	REITERATE	Buy

Earnings setup

Estimates

−$0.08

EPS estimate, this quarter

+26%

estimate change, 90 days

1↑ 0↓

revisions, 30 days

Current-quarter EPS estimate

−$0.103

90d

−$0.103

60d

−$0.080

30d

−$0.076

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.08	-$0.08–-$0.07	+4.6%	$0.00
Next Q	-$0.08	-$0.09–-$0.07	+7.8%	$0.00
Current FY	-$0.32	-$0.33–-$0.29	+2.4%	$0.00
Next FY	-$0.33	-$0.42–-$0.22	-7.7%	$1.7M

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Recent

Sep 30, 2026

Clinical Trial

Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis

Phase 2 · COMPLETED

Sep 16, 2026

Press release

Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds

Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in recurrent pericarditis and extends cash runway into H1…

Sep 10, 2026

Press release

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

TORONTO, Sept. 10, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life…

Sep 9, 2026

Press release

Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

TORONTO, Sept. 9, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences…

Aug 31, 2026

Short interest

Short Interest: CRDL up 27% to 2.9M shares

Settlement 2026-08-31 | Days to cover: 1.64 | ≈2.51% of shares outstanding (est.)